News

The glaucoma drug, PF-03187207, is the lead development compound generated under the August 2004 collaboration agreement between Pfizer and NicOx, which is focused on the development of nitric

TroVax is Oxford Biomedica's lead cancer immunotherapy. A phase III trial of Trovax in renal cancer is ongoing. Under the terms of the agreement, Sanofi will make payments

Patients enrolled in the trial will receive treatment with either Zingo or placebo approximately one to three minutes prior to the peripheral venous access procedure. Anesiva said it

In October 2006, the FDA issued a non-approvable letter to Replidyne for faropenem and the FDA recommended further clinical studies for the drug. The FDA did not raise

However, Health Canada said there have been no Canadian reports of deaths or psychiatric adverse events such as abnormal or suicidal behavior in children or teenagers. Last week

The companies said their VEGF Trap-Eye product met its primary endpoint of a statistically significant reduction in retinal thickness after 12 weeks. The product also reached a key

The submission to the FDA is based on results from two large phase III studies which showed Xelox to be as effective, in terms of progression-free survival, as

Neugranin is a long-acting form of Granulocyte Colony Stimulating Factor (G-CSF). CoGenesys believes that Neugranin has the potential to be the second long-acting G-CSF product to enter the

Massachusetts Biologic Laboratories will continue to distribute the tetanus diphtheria vaccine free of charge to the residents of the Commonwealth of Massachusetts. The three-year agreement begins in September,